Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Methods of Treating Autoimmune Diseases with DLL4 Antagonists

a technology of dll4 and autoimmune diseases, applied in the field of treating a disease, disorder, or condition, can solve the problems of notch signaling in controlling the origin and development of dcs and consequently treg homeostasis is still unknown

Inactive Publication Date: 2014-09-11
REGENERON PHARM INC
View PDF2 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent discusses the use of an antibody that targets Dll4, a protein involved in the immune system, to treat autoimmune diseases such as multiple sclerosis and diabetes. The antibody prevents Dll4 from interacting with certain receptors on immune cells, which results in a reduction or prevention of disease symptoms. The patent also suggests that increasing the number of regulatory T cells, which are known to protect against autoimmunity, can be achieved by using the Dll4 antagonist. Additionally, the patent suggests that the antibody could be used as a preventative measure for individuals who are at risk of developing the diseases or as a treatment for organ transplant recipients to prevent rejection or graft-versus-host disease.

Problems solved by technology

However, the role of Notch signaling in controlling the origin and the development of DCs and consequently Treg homeostasis is still unknown.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods of Treating Autoimmune Diseases with DLL4 Antagonists
  • Methods of Treating Autoimmune Diseases with DLL4 Antagonists
  • Methods of Treating Autoimmune Diseases with DLL4 Antagonists

Examples

Experimental program
Comparison scheme
Effect test

example 1

Effect of Dll4 Blockade on Development of B Cells, Dendritic Cells and T Cells

[0073]It has been shown that Dll4-Notch1 inhibition leads to a complete block in T cell development accompanied by ectopic appearance of B cells and an expansion of dendritic cells (DC) that can arise from Pro-T cell to DC fate conversion within the thymus (Hozumi et al., 2008, J Exp Med 205(11):2507-2513; Koch et al., 2008, J Exp Med 205(11):2515-2523; and Feyerabend et al., 2009, Immunity 30:1-13). It is, however, still unknown as to which specific stage of DC development is directly affected by the Dll4 blockade.

[0074]To answer this question, 6 week-old C57B1 / 6 mice (Jackson Labs) were injected subcutaneously with 5 or 25 mg / kg of anti-Dll4 Ab (REGN577) (n=5) or human Fc fragment (control) (n=5), twice a week for two weeks. REGN577 was prepared in-house based on the published sequence (WO 2007 / 143689). REGN 577 binds to human and mouse Dll4, but does not detectably binds human Dll1 and JAG1. Fourteen (1...

example 2

Effect of Dll4 Deletion on T Cell Development

[0082]To evaluate if the effect of Dll4 on DC development observed in Example 1 above was intrinsic to Dll4, DLL4COIN mice, in which Dll4 is conditionally inactivated, were prepared. “Conditional-by-inversion (COIN)” alleles are conditional alleles that rely on an inversible element (“COIN element”) to provide recombinase-mediated conditional mutations. DLL4COIN mice contain a tamoxifen-inducible Cre recombinase construct, CreERT2, which encodes a Cre recombinase fused to a mutant estrogen ligand-binding domain (ERT2). CreERT2 is essentially inactive in the absence of tamoxifen and is also not activated by endogenous estrogens. Tamoxifen treatment of the mice will activate CreERT2 and cause the inversion of the COIN element, which abrogates the transcription of all exons downstream of the COIN insertion point, thereby knocking out Dll4. For details of CreERT2 recombinase system, see Feil et al., 1997, Biochemical and Biophysical Research ...

example 3

Effect of Dll4 Blockade or Dll4 Deletion on Tregs Homeostasis

[0085]It has been recently shown that Tregs are essential for maintaining normal number of DCs. Upon Treg depletion there is a compensatory Fms-like tyrosine kinase 3 (Flt3)-dependent increase of DCs (Liu et al., 2009, supra). Furthermore, two independent groups showed a feedback control of regulatory T cell homeostasis by DCs in vivo; i.e., increasing the numbers of DCs leads to an increased Treg division and accumulation, which could prevent autoimmune disease development (Darrasse-Jeze G. et al., 2009, J Exp. Med. 206(9):1853-1862; and Swee L K et al., 2009, Blood 113(25):6277-6287).

[0086]To determine if Dll4 blockade could affect Treg homeostasis, Treg numbers in thymi of the mice treated with the Dll4 Ab or human Fc (control) in Example 1 were measured by flow cytometry. As shown in FIG. 7A, Dll4 blockade resulted in a robust expansion of Tregs within the thymus at day 14 after the initial injection. The expansion of ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides methods of treating a disease or disorder, in which increasing the number of regulatory T cell (Treg) is beneficial, by administering to a subject suffering from such a disease or disorder a therapeutically effective amount of Dll4 antagonists that block Dll4-Notch signal pathways, thereby increasing the number of Treg. Diseases or disorders treatable by the methods of the invention include autoimmune diseases or disorders, such as multiple sclerosis (MS), diabetes, and the like. Suitable Dll4 antagonists for the invention include antibodies or antibody fragments that specifically bind Dll4 and block Dll4-Notch interactions, the extracellular domain of Dll4, and the like. The invention also provides methods of preventing an occurrence or recurrence of such diseases or disorders in a subject predisposed or susceptible to developing such diseases or disorders. Furthermore, the methods of the invention are useful in preventing or treating organ transplant rejections or graft-versus-host disease.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application is a continuation of U.S. application Ser. No. 13 / 015,637 filed Jan. 28, 2011, which claims the benefit under 35 U.S.C §119(e) of U.S. provisional application nos. 61 / 299,801 filed Jan. 29, 2010; 61 / 361,687 filed Jul. 6, 2010; and 61 / 388,697 filed Oct. 1, 2010, all of which are herein specifically incorporated by reference in their entirety.REFERENCE TO A SEQUENCE LISTING[0002]This application includes an electronic sequence listing in a file named “446650-Sequence.txt”, created May 22, 2014 and containing 48,209 bytes, which is hereby incorporated by reference in its entirety for all purposes.BACKGROUND OF THE INVENTION[0003]1. Field of the Invention[0004]This invention relates to methods of treating a disease, disorder, or condition, in which increasing the number of regulatory T cells (Treg cells or Tregs) is beneficial, using delta-like ligand 4 (Dll4) antagonists. More specifically, the methods of the invention can t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K39/395C07K16/18A61K45/06
CPCA61K39/3955C07K16/18A61K45/06A61K2039/505C07K2317/73C07K16/28A61P1/04A61P1/16A61P19/02A61P21/00A61P21/04A61P25/00A61P29/00A61P35/00A61P37/00A61P37/02A61P37/06A61P5/14A61P7/00A61P7/06A61P3/10A61K38/13A61K38/28C07K16/22A61K2300/00A61K39/39533C07K2317/76C07K2317/565
Inventor SKOKOS, DIMITRIS
Owner REGENERON PHARM INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com